One-third of older adults with cognitive disorders are taking prescription drugs that could harm them

Introduction

Recent research has uncovered a troubling pattern among seniors living with cognitive disorders such as dementia. Approximately one‑third of adults aged 65 and older who have these conditions are being prescribed medications that may exacerbate their health problems rather than alleviate them. The drugs in question are often used to manage central nervous system (CNS) issues—anxiety, insomnia, and psychosis—but in a population already vulnerable to cognitive decline, they can trigger a cascade of adverse outcomes, including more frequent emergency‑room visits, longer hospital stays, worsening mental health, and an elevated risk of premature death.

What Happened

The study, which analyzed national prescription and health‑care utilization data, found that 33 % of older adults with documented cognitive impairment were taking at least one CNS‑active medication known to carry heightened risks for this group. These medications include benzodiazepines, non‑benzodiazepine sleep aids, antipsychotics, and certain antidepressants. Researchers observed that patients on these drugs were significantly more likely to experience falls, delirium, and medication‑related hospital admissions compared with peers who were not on such agents.

Beyond the immediate clinical consequences, the findings highlight a systemic issue: many prescribers continue to rely on pharmacologic solutions for behavioral and psychological symptoms of dementia (BPSD) despite growing evidence that non‑pharmacologic interventions can be safer and equally effective. The study’s authors warn that without a shift in prescribing culture, the health‑care system will face rising costs and poorer quality of life for a rapidly growing segment of the population.

Key Details

Among the CNS‑active drugs examined, benzodiazepines were the most common, accounting for roughly 18 % of the prescriptions identified. Antipsychotics followed at 12 %, while sleep agents such as zolpidem made up the remaining 3 %. The researchers noted that the risk profile of these medications is amplified in older adults with cognitive disorders because age‑related changes in liver and kidney function slow drug clearance, and the blood‑brain barrier becomes more permeable, allowing higher concentrations of the drug to affect brain tissue.

In addition to medication type, the study identified several contributing factors: co‑existing chronic illnesses (e.g., heart failure, diabetes), polypharmacy (the use of five or more medications), and limited access to specialized geriatric or psychiatric care. Patients living in long‑term care facilities were especially likely to receive antipsychotics, often for managing agitation or aggression, despite regulatory warnings about increased mortality risk in this group.

Background

The use of CNS‑active drugs in older adults has long been a point of contention. While these agents can provide short‑term relief for anxiety, insomnia, or psychosis, they also carry well‑documented side effects such as sedation, dizziness, and impaired cognition. In people already experiencing memory loss or executive dysfunction, these side effects can accelerate functional decline and increase dependence on caregivers.

Over the past decade, professional societies—including the American Geriatrics Society and the American Psychiatric Association—have issued guidelines urging clinicians to limit the use of high‑risk medications in dementia patients. Initiatives such as “Choosing Wisely” and deprescribing campaigns have sought to raise awareness, yet implementation remains uneven across health‑care settings, especially where staffing shortages and limited training in geriatric pharmacology persist.

Why It Matters

From a public‑health perspective, the implications are profound. The United States is projected to have more than 13 million people living with dementia by 2050. If a third of this population continues to be exposed to potentially harmful medications, the cumulative burden on emergency departments, inpatient units, and long‑term care facilities will be substantial. Moreover, each adverse drug event can diminish quality of life, increase caregiver stress, and accelerate the transition from community living to institutional care.

Economically, medication‑related complications are costly. Hospitalizations for falls or delirium average $15,000–$30,000 per admission, and repeat visits quickly add up. By reducing unnecessary CNS‑active prescriptions, health systems could save billions while simultaneously improving outcomes for a vulnerable demographic.

What Happens Next

In response to the study, several health‑care organizations are piloting comprehensive medication‑review programs that integrate pharmacists, geriatricians, and mental‑health specialists. These programs aim to identify high‑risk drugs, assess the necessity of each prescription, and implement tapering or substitution strategies where appropriate. Early data from pilot sites suggest a 20 % reduction in antipsychotic use and a corresponding drop in fall‑related admissions.

Policy makers are also taking note. The Centers for Medicare & Medicaid Services (CMS) is considering new quality metrics that would reward facilities for lower rates of high‑risk CNS medication use among dementia patients. Simultaneously, educational campaigns targeting primary‑care physicians are being expanded to emphasize non‑pharmacologic alternatives—such as behavioral therapy, environmental modifications, and caregiver support—that can mitigate BPSD without exposing patients to drug‑related hazards.

Conclusion

The revelation that one‑third of older adults with cognitive disorders are on prescription drugs that may harm them underscores a critical gap in our health‑care delivery system. While these medications can be indispensable for certain conditions, their indiscriminate use in a population already prone to cognitive decline poses serious risks. By embracing rigorous medication reviews, strengthening deprescribing initiatives, and prioritizing safer, non‑drug therapies, clinicians, policymakers, and caregivers can work together to protect the health, dignity, and longevity of seniors living with dementia and related disorders.